Clinical trials: Sleeplessness
Sleep Disturbance, Poor Sleep Quality
A Trial to Examine the Efficacy of a Supplement Gummy to Improve Sleep Quality and Quantity
This single-group trial evaluates the efficacy of FlavCity's Sleep Gummy supplement on sleep health in adults aged 20-50 who self-report issues with sleep.
- Conditions
- Sleep Disturbance, Poor Sleep Quality, Insomnia (Self-reported, Non-diagnosed)
- Trial name
- NCT07781332
- Testing
- Sleep Gummy Intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- DTBE, LLC dba FlavCity
Primary Insomnia
A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia
The purpose of this study is to further explore an effective dose range of PD0200390 for the treatment of patients with insomnia.
- Trial name
- NCT00551148
- Testing
- PD 0200390
- Where
- 16 sites in United States
- Volunteers
- 92 people
- Sponsor
- Pfizer
Insomnia
A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006
Part A: The purpose of this study is to evaluate the safety and tolerability of single oral doses of E2006 administered in the morning to healthy male and female subjects.
- Trial name
- NCT01463098
- Testing
- E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg
- Where
- 2 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Insomnia
Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)
The purpose of this study is to determine if esmirtazapine (Org 50081) is a safe and effective treatment for insomnia. It was anticipated that esmirtazapine would increase mean Total Sleep Time (TST) as recorded in sleep diaries…
- Trial name
- RUBY (NCT00482612)
- Testing
- Esmirtazapine
- Volunteers
- 526 people
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia, Sleep
Frequen-ZZZ SleepPad Investigational Device POC
The investigators propose to examine the potential effects of the Frequen- ZZZ sleep pad - a noninvasive, unobtrusive appliance that generates a localized low-level electromagnetic field via radiofrequency, and that is used on…
- Conditions
- Insomnia, Sleep, Sleep Disturbance
- Trial name
- NCT05908344
- Testing
- Activated Sleep Pad system (Frequen-ZZZ), Deactivated Sleep Pad system (Frequen-ZZZ)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Kunasan Inc.
Insomnia
Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)
This study will evaluate the safety, tolerability, and effect of multiple doses of suvorexant (MK-4305) on respiratory function in participants with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01293006
- Testing
- suvorexant
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia, Sleep Initiation and Maintenance Disorders
Zolpidem (Myslee) Post Marketing Study in Adolescent Patients With Insomnia - Evaluation With Polysomnography
To evaluate the efficacy of zolpidem for adolescent insomniacs with polysomnography
- Trial name
- NCT00653562
- Testing
- zolpidem
- Where
- 4 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Astellas Pharma Inc
Primary Insomnia
A Study of Gaboxadol in Primary Insomnia
To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia.
- Trial name
- NCT00209924
- Testing
- Gaboxadol
- Where
- Sweden
- Volunteers
- 505 people
- Sponsor
- H. Lundbeck A/S
Insomnia, Generalized Anxiety Disorder
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder.
- Trial name
- NCT00235508
- Testing
- Eszopiclone (Lunesta)
- Where
- 64 sites in United States
- Volunteers
- 420 people
- Sponsor
- Sumitomo Pharma America, Inc.
Obstructive Sleep Apnea, Insomnia
Evaluation of APAP With SensAwake in OSA and Insomnia Patients
The hypothesis is that APAP with SensAwake improves wake-after sleep onset compared to APAP without SensAwake in a patient population with Obstructive Sleep Apnea Syndrome (OSAS) and Insomnia.
- Trial name
- NCT02721329
- Testing
- APAP, APAP with SensAwake
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Fisher and Paykel Healthcare
Posttraumatic Stress Disorder (PTSD), Sleep Disturbances and Insomnia
A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances
Post-traumatic stress disorder (PTSD) affects many people who have experienced traumatic events. A common issue with PTSD is severe sleep disturbances, such as nightmares.
- Trial name
- PTSD-PoC (NCT06685965)
- Testing
- RE03
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- Reconnect Labs
Insomnia Disorder
Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder
This study evaluates the dose response of ACT-541468 on the change of wake after sleep onset (WASO) assessed by polysomnography (PSG) on the first 2 days of each treatment period.
- Trial name
- NCT02841709
- Testing
- ACT-541468
- Where
- 10 sites in United States, Germany
- Volunteers
- 58 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Insomnia
Efficacy and Tolerability of Tasipimidine in Sleepless Patients
The goal of this trial is to learn if tasipimidine will help in the treatment of insomnia and how safe it is to use in sleepless people.
- Trial name
- Unitas (NCT06956495)
- Testing
- Tasipimidine
- Where
- Finland
- Volunteers
- 190 people
- Sponsor
- Orion Corporation, Orion Pharma
Insomnia
VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia
The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.
- Trial name
- NCT00291187
- Testing
- 20 mg VEC-162, 50 mg VEC-162, 100 mg VEC-162
- Where
- 19 sites in United States
- Volunteers
- 411 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Insomnia
Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients
To investigate the safety and efficacy of administration of eszopiclone for 6 months in insomnia participants.
- Trial name
- NCT02455271
- Testing
- Eszopiclone
- Where
- 2 sites in Japan
- Volunteers
- 438 people
- Sponsor
- Eisai Co., Ltd.
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Insomnia, Sleep
Vestibular Nerve Stimulation to Improve Sleep
A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS) compared to a sham control a as a means of improving sleep as measured by ISI scores and EEG recordings The…
- Conditions
- Insomnia, Sleep, Sleep Disorders, Circadian Rhythm
- Trial name
- NCT04219566
- Testing
- VeNS
- Where
- India
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Sleep, Obstructive Sleep Apnea
Study Watch Sleep Metric Performance Characterization Study
This is a multi-center, single-arm, prospective performance evaluation study designed to assess performance of sleep metrics calculated from sensor data that is collected from two versions of the Verily Study Watch as compared to…
- Conditions
- Sleep, Obstructive Sleep Apnea, Insomnia
- Trial name
- NCT05276362
- Testing
- Study Watch, Actiwatch
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Verily Life Sciences LLC
Chronic Insomnia
Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.
The purpose of this study is to determine the subjective treatment effects of ramelteon, once daily (QD), on sleep using a post sleep questionnaire-interactive voice response system in adults with chronic insomnia.
- Trial name
- NCT00414102
- Testing
- Ramelteon
- Where
- 52 sites in United States
- Volunteers
- 552 people
- Sponsor
- Takeda
Insomnia
Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)
This study will be conducted to demonstrate, using polysomnography, that lemborexant 10 milligrams (mg) and 5 mg is superior to placebo on objective sleep onset as assessed by latency to persistent to sleep (LPS) after the last 2…
- Trial name
- SUNRISE 1 (NCT02783729)
- Testing
- Lemborexant, Zolpidem tartrate
- Where
- 102 sites in United States, Canada and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Eisai Inc.